SEEGNAL INC. ANNOUNCES THE APPOINTMENT OF ELAD BIBI-AVIV AS NEW CHIEF EXECUTIVE OFFICER

Executive Summary

• Seegnal Inc. announced the appointment of Elad Bibi‑Aviv as its new Chief Executive Officer, effective December 16 2025.
• The board also granted Bibi‑Aviv stock options to purchase up to 1,359,571 common shares at $0.80 per share, exercisable for ten years.
• The leadership transition is positioned to accelerate Seegnal’s growth and expansion of its AI‑driven clinical decision‑support platform globally.

Key Details

• New CEO: Elad Bibi‑Aviv, Esq., with prior experience founding Covary (insurtech) and leading NeuroKaire (AI health‑technology).
• Effective Date: December 16 2025.
• Predecessor Role Change: Former CEO Eyal Schneid will become General Manager of Seegnal E‑Health Ltd., the Israeli operating subsidiary.
• Board Comment: Chairman Nir Dor highlighted Bibi‑Aviv’s AI and healthcare sales expertise as critical for scaling Seegnal’s platform and delivering cost savings to insurers and HMOs.
• Equity Incentive Grant: Up to 1,359,571 common shares options at an exercise price of $0.80 per share; term of ten years from grant date.
• Strategic Outlook: Management expects the appointment to drive accelerated expansion into U.S., UAE, UK, Poland and other markets, leveraging existing adoption in Israeli hospitals.

Notable Quotes

“We are delighted to welcome Elad Bibi‑Aviv to Seegnal's leadership team. His proven experience in building AI companies and successfully selling to healthcare providers in the U.S. positions him perfectly to lead Seegnal through its next phase of growth.” – Nir Dor, Chairman

All forward‑looking statements are subject to risks and uncertainties detailed in Seegnal’s SEDAR filings.